BVF PARTNERS L P/IL

BVF Partners L.P./IL has demonstrated a net buying bias across its recent insider transactions, with $38.7 million in total purchases compared to $27.6 million in sales, according to SEC Form 4 filings. The firm’s activity has concentrated on three companies: Kymab Limited (KYMR), XOMA Corporation (XOMA), and ESSA Pharma Inc. (EPIX). Notably, BVF made significant purchases in KYMR on June 30, 2025, with transactions totaling approximately $13.95 million, including individual buys of $2.59 million, $5.09 million, and $6.27 million. In contrast, the firm executed sales in EPIX on August 5, 2025, with smaller dispositions valued at $20.66, $123.94, and $148.35 per transaction, alongside derivative dispositions (code "X") at nearly identical values. A larger sell-off occurred in XOMA on May 16, 2025, where BVF offloaded shares worth $7.19 million. Recent filings also show a series of unspecified transactions (coded "U") in RPTX and EPIX in early 2026 and late 2025, though these carried no reported dollar value. The firm’s trading pattern suggests selective positioning, with concentrated buys in KYMR offset by partial reductions in EPIX and XOMA. While BVF remains active across its holdings, the scale of its acquisitions in KYMR—far exceeding its recent sales—indicates a sustained investment in the biopharmaceutical sector. The absence of material transactions in other holdings, such as CBIO, OLMA, and MLTX, further narrows the focus of its recent activity to a few key positions.